SAWT BEIRUT INTERNATIONAL

| 29 March 2024, Friday |

Japan approves rheumatoid drug Baricitinib for COVID-19 patients

Japan’s health ministry approved on Friday the use of rheumatoid arthritis drug Baricitinib for COVID-19 patients, the third such approval following the drugs remdesivir and dexamethasone.

Eli Lilly & Co’s Japan subsidiary had applied to regulators for the new use of the drug in December.

    Source:
  • Reuters